Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas

Model scores of the 29,894 trials active now.

Model score 29% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientmribrainventricularserum
  Phrases that lowered it: weekspharmacokineticsevaluatereceiptopen
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 28.4% (raises risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 91.7% (raises risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports before start: 3785 (raises risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma NCT01817751 · started 2013 · scored riskier than 99% of active trials completed
• A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas NCT00995007 · started 2009 · scored riskier than 70% of active trials completed
• Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma NCT01989052 · started 2014 · scored riskier than 89% of active trials terminated
• Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure NCT01954030 · started 2013 · scored riskier than 96% of active trials terminated
• Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma NCT00883688 · started 2009 · scored riskier than 94% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.